Tag: Australian Pharma

Biocon and Mylan Launched Semglee® in Australia

biocon
Biocon Ltd and Mylan N.V. announced the launch of Semglee® (insulin glargine solution for injection 100 IU/mL in a 3mL pre-filled pen), the first insulin glargine biosimilar in Australia available on ...

First Australian Company to Gain T-Cell GMP Manufacturing Licence

The licence allows for the collection, manufacturing, testing, storage and release for the supply of any commercial T-Cell product. The Therapeutic Goods Administration (TGA) of Australia has grant...

FUJIFILM in Exclusive Licensing Agreement with Cynata

FUJIFILM Corporation announced that it has signed an exclusive licensing agreement with Cynata Therapeutics Limited (Chief Executive Officer: Ross Macdonald), an Australian bio-venture, to obtain worl...

Australian Researchers Developed and Tested New Type of Vaccine Targeting Tuberculosis

tb
Australian medical researchers from the Centenary Institute and the University of Sydney have successfully developed and tested a new type of vaccine targeting tuberculosis (TB), the world’s top infec...

Australian Researchers Developed New Type of TB Vaccine

malaria vaccine
Australian researchers produce early-stage vaccine which is inhaled into the lungs. Australian medical researchers from the Centenary Institute and the University of Sydney have successfully develope...

Mylan & Biocon Launched Ogivri™, a Biosimilar to Herceptin®, in Australia

Biocon Ltd. and Mylan N.V. announced the launch in Australia of Ogivri™ (trastuzumab), a biosimilar to Herceptin® (trastuzumab), for the treatment of HER2-overexpressing breast cancer and metastatic s...

Mundipharma Australia to Commercialize Orexo’s Lead Product

Orexo AB, the fully integrated specialty pharmaceutical company addressing opioid addiction and pain, today announces the company has signed an agreement granting Mundipharma Pty Limited (Mundipharma ...

Updated Obligations for Drug Shortage in Australia

The Australian medicines regulator has updated its guidance on reporting obligations for pharmaceutical companies, mandating confidential reporting of all shortages. The document, published by the ...

PCI Pharma to Produce AusCann’s First Treatment of Chronic Pain

Medical cannabis company AusCann has chosen PCI Pharma to manufacture and release its first product designed to help treat chronic pain. PCI Pharma will produce and release AusCann’s solid hard she...

First Australian CBD-Based Epilepsy Drug

After receiving formal authorisation to sell its “CannEpil” epilepsy drug treatment in Australia in October, ASX listed biotech, MGC Pharmaceuticals, has reached another milestone, with the arrival of...